Fiscal Year 2015 Tuberous Sclerosis Complex Research Program (TSCRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Exploration – Hypothesis Development Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-15-TSCRP-EHDA	Investigators at all academic levels (or equivalent), or postdoctoral fellows	 Supports the initial exploration of innovative, high-risk, high-gain concepts in TSC research to lay the groundwork for future avenues of investigation. Preliminary or published data encouraged but not required. Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. Clinical trials not allowed. 	 The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is \$150,000 in direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	Pre-application (Letter of Intent): July 10, 2015 5:00 p.m. Eastern time (ET) Application: July 27, 2015 11:59 p.m. ET
Idea Development Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-15-TSCRP-IDA	Principal Investigator: Must be an independent investigator with a documented faculty appointment (or equivalent). Optional Qualified Collaborator: Must be at or above the level of Assistant Professor (or equivalent) and meets at least 10% level of effort on the proposed research project.	 Supports conceptually innovative, high-risk, and potentially high-reward research in the early stages of development that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Preliminary or published data required. Optional Features: Applications that include a Qualified Collaborator who meets criteria identified in the Program Announcement/ Funding Opportunity may apply for a higher level of funding. Clinical trials not allowed. 	 The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is \$450,000 in direct costs (\$600,000 in direct costs if requesting an Optional Qualified Collaborator). Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	Pre-application (Letter of Intent): July 10, 2015 5:00 p.m. ET Application: July 27, 2015 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Pilot Clinical Trial Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-15-TSCRP-PCTA	Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).	 Supports exploratory studies that produce diagnostic or therapeutic information, safety, and tolerability studies and studies to determine the mechanism of action. Should be aimed at obtaining preliminary data leading to the development of interventions, as well as clinical biomarkers. Scientific rationale and preliminary data required. 	 The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is \$300,000 in direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	Pre-application (Letter of Intent): July 10, 2015 5:00 p.m. ET Application: July 27, 2015 11:59 p.m. ET